Table 2.

Sensitivity analysis and subgroup analysis

	Unadjusted OR (95% CI)	Adjusted OR (95% CI)
Alternative exposure definition	1.079 (0.877–1.327)	1.170 (0.938–1.461)
1-year exposure ascertainment time window	1.148 (0.902–1.398)	1.098 (0.867–1.423)
Non-insulin subgroup	1.173 (0.936–1.471)	1.299 (1.001–1.985)
Non-AD subgroup	1.074 (0.877–1.314)	1.054 (0.854–1.300)
Sulfonyl urea comparison subgroup	1.097 (0.884–1.362)	1.074 (0.769–1.500)
Thiazolidinedione comparison subgroup	1.083 (0.800–1.465)	0.695 (0.403–1.199)
Male subgroup	1.019 (0.745–1.394)	1.099 (0.781–1.546)
Female subgroup	1.081 (0.843–1.387)	1.190 (0.907–1.562)

Adjusted odds ratio are presented while controlling for covariates similar to the base-case analysis

AD autoimmune disease, OR odds ratio, Alternative exposure definition at least 60 days of DPP-4 therapy